Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action.
Drucker
Daniel J
DJ
Department of Medicine, Banting and Best Diabetes Centre, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Ontario, Canada. d.drucker@utoronto.ca
D058892:Adenosine Deaminase Inhibitors; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D018819:Dipeptidyl Peptidase 4; D054873:Dipeptidyl-Peptidase IV Inhibitors; D005749:Gastric Inhibitory Polypeptide / Q000378:metabolism; D006023:Glycoproteins / Q000037:antagonists & inhibitors*; D006801:Humans; D011480:Protease Inhibitors / Q000627:therapeutic use*; D012633:Secretin / Q000502:physiology; D013379:Substrate Specificity
D058892:Adenosine Deaminase Inhibitors; D054873:Dipeptidyl-Peptidase IV Inhibitors; D006023:Glycoproteins; D011480:Protease Inhibitors; D012633:Secretin; D005749:Gastric Inhibitory Polypeptide; C042807:DPP4 protein, human; D018819:Dipeptidyl Peptidase 4